Ernest Choy, MD, FRCP

Ernest Choy, MD, FRCP
 

Head of Rheumatology and Translational Research
Institute of Infection and Immunity
Director of Arthritis Research UK CREATE Centre and
Welsh Arthritis Research Network (WARN) Cardiff University School of Medicine
Cardiff, United Kingdom


When are combination approaches -- with a DMARD and biologic -- used to treat RA and when might monotherapeutic approaches be preferable?

When are combination approaches — with a DMARD and biologic — used to treat RA and when might monotherapeutic approaches be preferable?

Can you compare the translational implications of inhibiting the TNF vs IL-6 cytokine signaling systems? How are these differences manifested clinically?

Can you compare the translational implications of inhibiting the TNF vs IL-6 cytokine signaling systems? How are these differences manifested clinically?

What disease activity measures for RA do you consider to be most important?

What disease activity measures for RA do you consider to be most important?

Is there a systematic approach for aligning specific cohorts of patients with RA with specific therapies? With IL-6 inhibitors, TNFIs, or co-modulating activating agents?

Is there a systematic approach for aligning specific cohorts of patients with RA with specific therapies? With IL-6 inhibitors, TNFIs, or co-modulating activating agents?

Can you discuss the unique mechanistic effects of IL-6 inhibition -- including the role of GP 130 -- that differentiate it from other cytokines that are targeted in RA?

Can you discuss the unique mechanistic effects of IL-6 inhibition — including the role of GP 130 — that differentiate it from other cytokines that are targeted in RA? Can its signaling properties be transmitted to sites distal from inflammation?

What biomarkers, clinical findings, or previous treatment history do you rely on to identify patients who might be uniquely responsive to IL-6 inhibition?

What biomarkers, clinical findings, or previous treatment history do you rely on to identify patients who might be uniquely responsive to IL-6 inhibition?

How does the IL-6 pathway and family of cytokines affect inflammation and non-joint clinical manifestations?

How does the IL-6 pathway and family of cytokines affect inflammation and non-joint clinical manifestations?

What new data related to the use of TNFIs and the use of IL-6 inhibitors do we have as it relates to drug persistence and safety profiles?

What new data related to the use of TNFIs and the use of IL-6 inhibitors do we have as it relates to drug persistence and safety profiles?